<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00249379</url>
  </required_header>
  <id_info>
    <org_study_id>NIAAAWEA-K23-00222-B</org_study_id>
    <secondary_id>K23AA000222</secondary_id>
    <nct_id>NCT00249379</nct_id>
  </id_info>
  <brief_title>Study of Acamprosate to Prevent Alcohol Relapse in Criminal Justice Supervisees</brief_title>
  <official_title>The Use of Acamprosate for Preventing Alcohol Relapse Among Alcohol Dependent Drug Treatment Court Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test how tolerable and effective acamprosate is when used to
      prevent alcohol relapse in criminal justice supervisees (those on probation, parole, or in
      drug court).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acamprosate has been an available treatment for alcohol dependence outside the United States
      and has recently been approved by the U.S. Food and Drug Administration as an effective
      therapy for alcohol dependence. In the past ten years, drug court programs have been
      implemented as one possible solution to reduce the burden placed on state and federal
      correctional systems. These programs are generally focused on non-violent drug dependent
      offenders and are offered as an alternative to incarceration. However, the use of acamprosate
      has never been examined for alcohol relapse prevention among a drug court population, or
      among those on probation or parole.

      Comparison: Alcohol-dependent criminal justice supervisees who receive acamprosate, compared
      to participants who do not receive acamprosate.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Not enough sugjects enrolled before funding ran out
  </why_stopped>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drinking and Other Drug Use</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of participants using alcohol and other drugs during 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of Acceptance</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of participants taking study medication during 12 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retention in Drug Court</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of participants remaining in drug treatment court program during 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recidivism Rates</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of participants returning to jail during 12 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>Acamprosate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to receive acamprosate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No medication</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No medication intervention (subjects do not receive acamprosate), but do receive Building Social Networks counseling</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acamprosate</intervention_name>
    <description>Subjects randomized to receive acamprosate 333 mg tablets to be taken 3 times daily to prevent relapse to alcohol dependence</description>
    <arm_group_label>Acamprosate</arm_group_label>
    <other_name>Campral</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of alcohol dependence in the year before entering criminal justice supervision

          -  Currently under criminal justice supervision (drug court, probation, or parole) in
             central Virginia

        Exclusion Criteria:

          -  Pregnant or nursing a baby

          -  Known sensitivity to acamprosate

          -  Elevated serum creatinine level or other evidence of kidney problems

          -  Symptoms of severe depression or suicidal ideation

          -  Non-English speaking such that they cannot provide informed consent

          -  Cognitive impairment such that they cannot provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael F. Weaver, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2005</study_first_submitted>
  <study_first_submitted_qc>November 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2005</study_first_posted>
  <results_first_submitted>January 3, 2012</results_first_submitted>
  <results_first_submitted_qc>April 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 11, 2016</results_first_posted>
  <last_update_submitted>April 29, 2016</last_update_submitted>
  <last_update_submitted_qc>April 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alcohol dependence</keyword>
  <keyword>Acamprosate(drug)</keyword>
  <keyword>Drug Court</keyword>
  <keyword>Probation</keyword>
  <keyword>Parole</keyword>
  <keyword>Criminal justice</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Acamprosate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Acamprosate</title>
          <description>Criminal justice supervisees given acamprosate 333 mg, 2 tablets orally 3 times daily for alcohol dependence for a 12-week period</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>No specific intervention, received standard Drug Court counseling, monitored for outcomes</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Acamprosate</title>
          <description>Criminal justice supervisees given acamprosate for alcohol dependence</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>No specific intervention, monitored for outcomes</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.9" spread="3"/>
                    <measurement group_id="B2" value="37.9" spread="3"/>
                    <measurement group_id="B3" value="37.9" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Drinking and Other Drug Use</title>
        <description>Number of participants using alcohol and other drugs during 12 weeks</description>
        <time_frame>12 weeks</time_frame>
        <population>Only 13 Acamprosate participants were analyzed because one participant was lost to follow-up after being given an initial supply of medication for the study.
No data were collected for the Control Arm because funding ran out for the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Acamprosate</title>
            <description>participants taking study medication</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
          </group>
        </group_list>
        <measure>
          <title>Drinking and Other Drug Use</title>
          <description>Number of participants using alcohol and other drugs during 12 weeks</description>
          <population>Only 13 Acamprosate participants were analyzed because one participant was lost to follow-up after being given an initial supply of medication for the study.
No data were collected for the Control Arm because funding ran out for the study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Level of Acceptance</title>
        <description>Number of participants taking study medication during 12 weeks</description>
        <time_frame>12 weeks</time_frame>
        <population>Only 13 Acamprosate participants were analyzed because one participant was lost to follow-up after being given an initial supply of medication for the study.
No data were collected for the Control Arm because funding ran out for the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Acamprosate</title>
            <description>participants taking study medication</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
          </group>
        </group_list>
        <measure>
          <title>Level of Acceptance</title>
          <description>Number of participants taking study medication during 12 weeks</description>
          <population>Only 13 Acamprosate participants were analyzed because one participant was lost to follow-up after being given an initial supply of medication for the study.
No data were collected for the Control Arm because funding ran out for the study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Retention in Drug Court</title>
        <description>Number of participants remaining in drug treatment court program during 12 weeks</description>
        <time_frame>12 weeks</time_frame>
        <population>Only 13 Acamprosate participants were analyzed because one participant was lost to follow-up after being given an initial supply of medication for the study.
No data were collected for the Control Arm because funding ran out for the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Acamprosate</title>
            <description>participants taking study medication</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
          </group>
        </group_list>
        <measure>
          <title>Retention in Drug Court</title>
          <description>Number of participants remaining in drug treatment court program during 12 weeks</description>
          <population>Only 13 Acamprosate participants were analyzed because one participant was lost to follow-up after being given an initial supply of medication for the study.
No data were collected for the Control Arm because funding ran out for the study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recidivism Rates</title>
        <description>Number of participants returning to jail during 12 weeks</description>
        <time_frame>12 weeks</time_frame>
        <population>Only 13 Acamprosate participants were analyzed because one participant was lost to follow-up after being given an initial supply of medication for the study.
No data were collected for the Control Arm because funding ran out for the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Acamprosate</title>
            <description>participants taking study medication</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
          </group>
        </group_list>
        <measure>
          <title>Recidivism Rates</title>
          <description>Number of participants returning to jail during 12 weeks</description>
          <population>Only 13 Acamprosate participants were analyzed because one participant was lost to follow-up after being given an initial supply of medication for the study.
No data were collected for the Control Arm because funding ran out for the study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Acamprosate</title>
          <description>Criminal justice supervisees given acamprosate for alcohol dependence</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>No specific intervention, monitored for outcomes</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small numbers of subjects, significant number withdrew or were lost to follow-up</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Michael Weaver, MD</name_or_title>
      <organization>Virginia Commonwealth University</organization>
      <phone>804-828-1283</phone>
      <email>mweaver@mcvh-vcu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

